The success of corneal crosslinking (CXL) for ectatic disease requires oxygen within the tissue, and this dependency likely explains the limited efficiency of high-intensity (rapid) and transepithelial treatment protocols, said Farhad Hafezi, MD, PhD
In 2014, the readers of “The Ophthalmologist” voted for the PowerList, the 100 most influential personalities in global ophthalmology. ELZA member Farhad Hafezi is one of them.
EMAGine SA, a spin-off company from the University of Geneva and co-founded by Nikki and Farhad Hafezi, is elected amongst the best start-ups in Switzerland in 2014
An optimized treatment protocol, a miniaturized device that mounts on a slit lamp and a new photosensitizing agent may allow for a faster and more effective application of cross-linking for infectious keratitis in the near future.
